Search hospitals > California > Santa Monica

UCLA

Claim this profile
Santa Monica, California 90404
Global Leader in Lung Cancer
Global Leader in Pancreatic Cancer
Conducts research for Solid Tumors
Conducts research for Breast Cancer
Conducts research for Cancer
83 reported clinical trials
23 medical researchers
Photo of UCLA in Santa MonicaPhoto of UCLA in Santa MonicaPhoto of UCLA in Santa Monica

Summary

UCLA is a medical facility located in Santa Monica, California. This center is recognized for care of Lung Cancer, Pancreatic Cancer, Solid Tumors, Breast Cancer, Cancer and other specialties. UCLA is involved with conducting 83 clinical trials across 128 conditions. There are 23 research doctors associated with this hospital, such as Zev A. Wainberg, Lee Rosen, MD, J. Randolph Hecht, MD, and John Shen, M.D..

Area of expertise

1Lung Cancer
Global Leader
UCLA has run 21 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
EGFR positive
2Pancreatic Cancer
Global Leader
UCLA has run 16 trials for Pancreatic Cancer. Some of their research focus areas include:
Stage IV
Stage III
KRAS positive

Top PIs

Clinical Trials running at UCLA

Colorectal Cancer
Lung Cancer
Pancreatic Cancer
Solid Tumors
Ovarian Cancer
Breast Cancer
Cancer
Gastrointestinal Stromal Tumor
Postoperative Pain
Renal Cell Carcinoma
Image of trial facility.

Amivantamab + Chemotherapy vs Cetuximab + Chemotherapy

for Colorectal Cancer

The purpose of this study is to compare how long the participants are disease-free (progression-free survival) when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, oxaliplatin (mFOLFOX6) or 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus cetuximab and mFOLFOX6 or FOLFIRI in adult participants with Kirsten rat sarcoma viral oncogene homolog (KRAS)/ Neuroblastoma RAS viral oncogene homolog (NRAS) and v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) wild type (WT) unresectable or metastatic left-sided colorectal cancer.
Recruiting2 awards Phase 34 criteria
Image of trial facility.

Amivantamab + FOLFIRI

for Colorectal Cancer

The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus either cetuximab or bevacizumab and FOLFIRI given to participants with Kirsten rat sarcoma viral oncogene/ neuroblastoma RAS viral oncogene homolog (KRAS/ NRAS) and v-raf murine sarcoma viral oncogene homolog B (BRAF) wild-type recurrent, unresectable or metastatic colorectal cancer who have previously received chemotherapy.
Recruiting2 awards Phase 34 criteria
Image of trial facility.

[225Ac]-FPI-2068

for Cancer

This is a first-in-human, Phase 1, non-randomized, multicenter, open-label clinical study designed to investigate the safety, tolerability, dosimetry, biodistribution, and pharmacokinetics (PK) of \[225Ac\]-FPI-2068, \[111In\]-FPI-2107, and FPI-2053 in metastatic and/or recurrent solid tumors (HNSCC, NSCLC, mCRC, PDAC, GC, RCC).
Recruiting1 award Phase 16 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at UCLA?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security